Form 4: Organon & Executive Reports Stock Transaction
Insider Transaction (Form 4)
Ferreira Juan Camilo Arjona, Head of R&D & CMO of Organon & Co., reported multiple transactions in common stock on August 11, 2026.
Summary
- Option exercise/conversion: acquired 11,519 Common Stock on August 11, 2026; holds 41,566 after (Direct).
- Tax/exercise-price withholding: disposed of 4,134 Common Stock at $13.62 ($56,305) on August 11, 2026; holds 37,432 after (Direct).
- Option exercise/conversion: acquired 11,519 Restricted Stock Units on August 11, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Ferreira Juan Camilo Arjona — Officer (Head of R&D & CMO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-11 | Option exercise/conversion | Common Stock | 11,519 | — | — | 41,566.477 |
| 2026-08-11 | Tax/exercise-price withholding | Common Stock | 4,134 | $14 | $56.3K | 37,432.477 |
| 2026-08-11 | Option exercise/conversion | Restricted Stock Units | 11,519 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-11 | Option exercise/conversion (11,519 shares) |
| 2026-08-11 | Tax/exercise-price withholding (4,134 shares) |
| 2026-08-11 | Option exercise/conversion (11,519 shares) |
Keywords
insider transaction, Form 4, OGN, Organon & Co., neutral, Ferreira Juan Camilo Arjona
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.